Wolverine Trading
RIGL icon

Wolverine Trading’s Rigel Pharmaceuticals RIGL Stock Holding History

Wolverine Trading’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$377K Buy
+13,100
New +$392K ﹤0.01% 4042
2024
Q4 		– Sell
-11,100
Closed -$182K – 5763
2024
Q3 		$182K Sell
11,100
-15,800
-59% -$186K ﹤0.01% 4149
2024
Q2 		$221K Buy
26,900
+23,500
+691% +$246K ﹤0.01% 3743
2024
Q1 		$50.3K Buy
3,400
+1,110
+48% +$15K ﹤0.01% 4215
2023
Q4 		$33.2K Buy
2,290
+800
+54% +$8.18K ﹤0.01% 4331
2023
Q3 		$16.1K Sell
1,490
-90
-6% -$1.08K ﹤0.01% 4343
2023
Q2 		$21.2K Sell
1,580
-460
-23% -$6.22K ﹤0.01% 4095
2023
Q1 		$27K Buy
+2,040
New +$32.4K ﹤0.01% 3962
2022
Q4 		– Sell
-2,100
Closed -$25K – 4863
2022
Q3 		$25K Buy
+2,100
New +$28.4K ﹤0.01% 4332
2022
Q2 		– Sell
-1,370
Closed -$41K – 5521
2022
Q1 		$41K Sell
1,370
-500
-27% -$13.5K ﹤0.01% 5128
2021
Q4 		$50K Sell
1,870
-2,140
-53% -$64.6K ﹤0.01% 5320
2021
Q3 		$146K Sell
4,010
-190
-5% -$7.48K ﹤0.01% 5567
2021
Q2 		$187K Buy
4,200
+10
+0.2% +$378 ﹤0.01% 5061
2021
Q1 		$142K Buy
4,190
+360
+9% +$14.3K ﹤0.01% 5268
2020
Q4 		$139K Buy
3,830
+2,190
+134% +$63.4K ﹤0.01% 4379
2020
Q3 		$38K Buy
+1,640
New +$40.3K ﹤0.01% 4314
2018
Q4 		– Sell
-2,300
Closed -$74K – 5189
2018
Q3 		$74K Sell
2,300
-760
-25% -$22.8K ﹤0.01% 4623
2018
Q2 		$108K Hold
3,060
– – ﹤0.01% 4696
2018
Q1 		$108K Buy
3,060
+1,880
+159% +$75.2K ﹤0.01% 4696
2017
Q4 		$46K Sell
1,180
-2,340
-66% -$89.1K ﹤0.01% 4618
2017
Q3 		$89K Buy
3,520
+670
+24% +$16.3K ﹤0.01% 4101
2017
Q2 		$80K Buy
+2,850
New +$78K ﹤0.01% 3960
2016
Q4 		– Sell
-1,080
Closed -$39K – 5004
2016
Q3 		$39K Sell
1,080
-160
-13% -$4.59K ﹤0.01% 4435
2016
Q2 		$27K Buy
+1,240
New +$30.8K ﹤0.01% 3880

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's RIGL Position: Q2 2024 in Review

Wolverine Trading sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 1,276 shares — an estimated $13.4K sold.

Wolverine Trading first reported a position in RIGL in Q2 2016 and held it in 10 quarters. The position peaked at $125K in Q3 2016. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Wolverine Trading reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 1,276 Rigel Pharmaceuticals shares in Q2 2024, an estimated $13.4K.
  • Wolverine Trading first reported a position in Rigel Pharmaceuticals in Q2 2016 and held it in 10 quarters.
  • Wolverine Trading's Rigel Pharmaceuticals position peaked at $125K in Q3 2016.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.